|
WO2016098016A1
|
|
Process for the preparation of sglt2 inhibitors
|
|
WO2016088074A1
|
|
Process for the preparation of amorphous ibrutinib
|
|
WO2016055945A1
|
|
Polymorphs of canagliflozin
|
|
WO2016035006A1
|
|
Novel nucleotide analogs, process for the preparation of sofosbuvir and its analogs, novel forms of sofosbuvir and solid dispersion of sofosbuvir
|
|
WO2016027243A1
|
|
Novel solid state forms of afatinib dimaleate
|
|
WO2016024243A2
|
|
Fidaxomicin polymorphs and processes for their preparation
|
|
WO2016005962A2
|
|
Stable liquid formulations of cyclophosphamide and processes
|
|
WO2015128793A1
|
|
A process for modifying high mannose and galactosylation content of a glycoprotein composition
|
|
WO2015104658A2
|
|
Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin
|
|
WO2014195861A2
|
|
Preparation of ticagrelor
|
